Creating new treatments to enhance cancer immunotherapy effectiveness
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies
This study is looking at new drugs that can help improve cancer treatments by targeting a protein called RIPK1, which plays a role in how our immune system fights cancer, especially for patients who haven't had success with current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10977426 on NIH RePORTER |
What this research studies
This research focuses on developing innovative drugs that target RIPK1, a protein involved in regulating immune responses and cell death in cancer. By understanding how RIPK1 functions, the researchers aim to improve the effectiveness of existing cancer immunotherapies, particularly for patients who do not respond to current treatments. The approach involves creating degraders that can selectively eliminate RIPK1, potentially transforming the tumor environment to make it more responsive to therapies like anti-PD1. Patients may be monitored for changes in their immune response and tumor behavior as part of this research.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced cancer who have not responded to existing immunotherapy treatments.
Not a fit: Patients with early-stage cancer or those who have not yet undergone immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments for patients who currently do not respond to immunotherapy.
How similar studies have performed: Previous studies have shown promising results with similar approaches targeting RIPK1, indicating potential for success in this novel treatment strategy.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Wang, Jin — Baylor College of Medicine
- Study coordinator: Wang, Jin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.